Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

mehr ...

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1664, Suchdauer: 0.64s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

von Post, Cathalijne C B ; de Boer, Stephanie M ; Powell, Melanie E ; et al.

Schlagworte: High risk endometrial cancer; chemoradiotherapt; radiotherapy; molecular classification; Settore MEDS-21/A - Ginecologia e ostetricia; Settore MEDS-09/A - Oncologia medica; Settore MEDS-22/A - Diagnostica per immagini e radioterapia
- View full text via BASE
Merkliste

2
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin

von Ugalde, A ; Tothill, RW ; Quinn, S ; et al.
- View full text via BASE
Merkliste

3
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, AB ; Gladieff, L ; O'Malley, DM ; et al.

The Lancet , 405 (10496) pp. 2205-2216. (2025)

Schlagworte: Science & Technology; Life Sciences & Biomedicine; Medicine; General & Internal; General & Internal Medicine; MIRVETUXIMAB SORAVTANSINE; PLUS GEMCITABINE; DIURNAL CORTISOL; FALLOPIAN-TUBE; RECURRENT; CHEMOTHERAPY; BEVACIZUMAB; PROGRESSION; SURVIVAL; 3-ARM
- View full text via BASE
Merkliste

4
70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpoints

von Lorusso, D. ; Gladieff, L. ; Gilbert, L. ; et al.

ESMO Open ; volume 10, page 105332 ; ISSN 2059-7029
- View full text via BASE
Merkliste

5
Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies

von Shahnam, A ; Hitchen, N ; Manoharan, S ; et al.
- View full text via BASE
Merkliste

6
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary

von Rebello, RJ ; Posner, A ; Dong, R ; et al.
- View full text via BASE
Merkliste

7
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study

von Westphalen, C.B. ; Federer-Gsponer, J. ; Pauli, C. ; et al.

In ESMO Open December 2023 8(6)
- View full text via DOI
Merkliste

8
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

von Vermij, Lisa ; Léon-Castillo, Alicia ; Singh, Naveena ; et al.

In Modern Pathology October 2022 35(10):1475-1483
- View full text via DOI
Merkliste

9
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study

von O'Malley, D.M. ; Bariani, G.M. ; Cassier, P.A. ; et al.

In Gynecologic Oncology August 2022 166(2):245-253
- View full text via DOI
Merkliste

10
Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

von Krämer, A. ; Bochtler, T. ; Pauli, C. ; et al.

In Annals of Oncology March 2023 34(3):228-246
- View full text via DOI
Merkliste

11
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

von Edmondson, R.J. ; O'Connell, R.L. ; Banerjee, S. ; et al.

In Gynecologic Oncology December 2021 163(3):524-530
- View full text via DOI
Merkliste

12
Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

von Burdett, NL ; Willis, MO ; Pandey, A ; et al.
- View full text via BASE
Merkliste

13
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

von Kristeleit, R ; Leary, A ; Oaknin, A ; et al.
- View full text via BASE
Merkliste

14
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer

von Olawaiye, AB ; Kim, JW ; Bagameri, A ; et al.
- View full text via BASE
Merkliste

15
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial

von Post, C ; De Boer, S ; Powell, M ; et al.

Schlagworte: endoometrial cancer, chemotherapy, radiotherapy, molecular classification; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

16
Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903)

von Friedlander, M. ; Benson, C. ; O'Connell, R.L. ; et al.

In Gynecologic Oncology April 2021 161(1):160-165
- View full text via DOI
Merkliste

17
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, A ; Gladieff, L ; O'Malley, D ; et al.

Schlagworte: chemotherapy; info:eu-repo/semantics/article
- Zum Volltext über OAIster
Merkliste

18
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

von Tabernero, J. ; Andre, F. ; Blay, J.-Y. ; et al.

In ESMO Open April 2022 7(2)
- View full text via DOI
Merkliste

19
Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia

von Gordon, Louisa G. ; Wood, C. ; Tothill, R. W. ; et al.

PharmacoEconomics - Open: Healthcare Interventions and Outcomes. 7(1):111-120
- Zum Volltext in PubMed Central
Merkliste

20
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial

von Werner, B ; Sjoquist, KM ; Espinoza, D ; et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
- View full text via BASE
Merkliste

21
Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial

von Khaw, P. ; Do, V. ; Lim, K. ; et al.

In Clinical Oncology March 2022 34(3):198-204
- View full text via DOI
Merkliste

22
Unravelling mutational signatures with plasma circulating tumour DNA

von Hollizeck, S ; Wang, N ; Wong, SQ ; et al.
- View full text via BASE
Merkliste

23
A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial – ANZGOG 1102

von Schofield, P. ; Gough, K. ; Pascoe, M. ; et al.

In Gynecologic Oncology December 2020 159(3):785-793
- View full text via DOI
Merkliste

24
200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study

von Bochtler, T. ; Krämer, A. ; Pauli, C. ; et al.

Annals of Oncology ; volume 35, page S296-S297 ; ISSN 0923-7534
- View full text via BASE
Merkliste

25
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

von Sivakumaran, T. ; Mileshkin, L. ; Grant, P. ; et al.

In Gynecologic Oncology July 2020 158(1):47-53
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag